Aminotriazine derivative and pharmaceutical composition comprising the same
US-9732060-B2 · Aug 15, 2017 · US
Aminotriazine derivative and pharmaceutical composition comprising the same
US10065941B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10065941-B2 |
| Application number | US-201715637967-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 29, 2017 |
| Priority date | Jun 14, 2013 |
| Publication date | Sep 4, 2018 |
| Grant date | Sep 4, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides novel compounds having a P2X 3 and/or P2X 2/3 receptor antagonistic activity. A compound of Formula (I): wherein R a and R b , and R d and R e are taken together to form oxo or the like; R 4a and R 4b are hydrogen or the like; n is 1 or the like; R 2 is aryl or the like; s and s′ is 0 or the like; R 9 and R 9 ′ are halogen or the like; R 20a and R 20b are hydrogen, alkyl or the like; u is 1 to 4; R 13 is hydrogen or the like, or its pharmaceutically acceptable salt.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating pain, comprising administering to a person in need thereof a pharmaceutically effective amount of a compound: or its pharmaceutically acceptable salt. 2. The method according to claim 1 , wherein the compound is the following formula: or its pharmaceutically acceptable salt. 3. The method according to claim 1 , wherein the compound is the following formula: or its pharmaceutically acceptable salt. 4. The method according to claim 1 , wherein the compound is the following formula: or its pharmaceutically acceptable salt.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Centrally acting analgesics, e.g. opioids · CPC title
Drugs for disorders of the respiratory system · CPC title
containing three or more hetero rings · CPC title
- C07D401/12Primary
linked by a chain containing hetero atoms as chain links · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10065941B2 cover?
- The present invention provides novel compounds having a P2X 3 and/or P2X 2/3 receptor antagonistic activity. A compound of Formula (I): wherein R a and R b , and R d and R e are taken together to form oxo or the like; R 4a and R 4b are hydrogen or the like; n is 1 or the like; R 2 is aryl or the like; s and s′ is 0 or the like; R 9 and R 9 ′ are halogen…
- Who is the assignee on this patent?
- Shionogi & Co
- What technology area does this patent fall under?
- Primary CPC classification C07D401/12. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).